Search Results

You are looking at 21 - 30 of 383 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

CRE24-042: Microgranular Acute Promyelocytic Leukemia Presenting as Recurrent Stroke and Isolated Neutropenia

Kevin Fitzpatrick O’Sullivan, Rushad Patell, and Jason Freed

through the stent despite adherence to apixaban and prasugrel and worsening neutropenia with an ANC of 0.430 K/uL. She was then re-admitted two months later with abdominal pain and worsening neutropenia with an ANC of 0.250 K/uL. Bone marrow biopsy

Full access

HSR24-146: Chemotherapy-Induced Febrile Neutropenia (FN) in the US: Healthcare Resource Utilization (HCRU) and Costs

Edward Li, Marie Yasuda, Jeanine Flanigan, and Chi‐Chang Chen

Background: Neutropenia is a well-established side effect of myelosuppressive chemotherapies that may increase the risk for fever/infection. Updated estimates of the HCRU and cost burden per FN episode are needed to inform treatment strategies

Full access

CLO23-048: Disparities in Outcomes of Chemotherapy-Related Febrile Neutropenia Patients: A Nationwide Study of Hospitalizations

Akhil Jain, Sohiel Deshpande, Krishna Desai, Sabah Iqbal, Aisha Sultan, Monika Garg, Bohdan Baralo, and Rajesh Thirumaran

Background: Febrile neutropenia (FN) being a life-threatening complication of chemotherapeutic drugs, demands extraordinary and distinct care than non neutropenic and septic patients. We used the National Inpatient Sample (NIS) database to

Full access

BPI20-011: Prescriber-Assigned Febrile Neutropenia and Emetic Risks Compared to the NCCN Risk Classification for Cancer Treatment Regimens

Kimberly Rose Hedstrom, Margaret Rausa, Eric Gratias, and Stephen Hamilton

Background: The National Comprehensive Cancer Network (NCCN) establishes standard of care for patients receiving anticancer therapy, and classifies regimens based on febrile neutropenia (FN) and emesis risks. eviCore healthcare licenses NCCN

Full access

Impact of Exercise on Chemotherapy Tolerance and Survival in Early-Stage Breast Cancer: A Nonrandomized Controlled Trial

Amy A. Kirkham, Karen A. Gelmon, Cheri L. Van Patten, Kelcey A. Bland, Holly Wollmann, Donald C. McKenzie, Taryne Landry, and Kristin L. Campbell

survival. 1 Proposed mechanisms for this positive effect on chemotherapy treatment tolerance include exercise-related amelioration of specific symptoms or toxicities that cause treatment reductions or delays, including neutropenia, fatigue, and neuropathy

Full access

HSR21-073: Febrile Neutropenia Outcomes Among Patients With Breast Cancer and Non-Hodgkin’s Lymphoma Receiving Pegfilgrastim Prophylaxis: A Real-World Analysis of Commercial and Medicare Claims From 2017-2018

Weijia Wang, Edward Li, Kim Campbell, and Ali McBride

Introduction: Febrile neutropenia (FN) is a major dose-limiting toxicity of myelosuppressive chemotherapy that can result in hospitalization, dose reductions or treatment delays and compromised clinical outcomes. National Comprehensive Cancer

Full access

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Jeffrey Crawford, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A. Griffiths, Shannon Hough, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Vivek Roy, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L. Burns, and Lenora Pluchino

used to reduce the incidence of neutropenia. Neutropenia is defined as an absolute neutrophil count (ANC) of <500 neutrophils/mcL or an ANC of <1,000 neutrophils/mcL and a predicted decline ≤500 neutrophils/mcL over the next 48 hours. Neutropenia can

Full access

Long-Term Outcomes of Myeloid Growth Factor Treatment

Gary H. Lyman and David C. Dale

M yeloid growth factors have been used for more than 20 years to ameliorate myelotoxicity after cancer chemotherapy and to prevent infections in patients with chronic neutropenia. Almost all data on long-term outcomes come from studies of

Full access

Guidelines of the National Comprehensive Cancer Network on the Use of Myeloid Growth Factors with Cancer Chemotherapy: A Review of the Evidence

Gary H. Lyman

Dr. Lyman has received research grant support from Amgen and GlaxoSmithKline and is on the speakers' bureau of Amgen and OrthoBiotech. References 1 Lyman GH Kuderer NM . Epidemiology of febrile neutropenia . Support Cancer Ther

Full access

Myeloid Growth Factors

Jeffrey Crawford, James Armitage, Lodovico Balducci, Pamela Sue Becker, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, David P. Steensma, Mahsa Talbott, Saroj Vadhan-Raj, Peter Westervelt, Michael Westmoreland, Mary Dwyer, and Maria Ho

Neutropenia (<500 neutrophils/mcL or <1000 neutrophils/mcL and a predicted decline to ≤500/mcL over the next 48 h) and resulting febrile neutropenia (FN; ≥38.3°C orally or ≥38.0°C over 1 h) can be induced by myelosuppressive chemotherapy. FN, in turn, is a